Across TCGA pan-cancer cohorts, MIR583 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated MIR583 data layer compared with 12 for mass-spec protein.
The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher MIR583 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated MIR583 expression acts as an unfavorable survival marker.
LIHC are the cancer types where MIR583 Mutation most reproducibly stratifies survival.